Return to homepagePandemic Pact

Drug repurposing for SARS-CoV-2 infection using human organoid culture technology [Funder: Genome BC, CIHR]

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Other Funders (Canada)

  • Principal Investigator

    Drs. François Jean, Leonard Foster, Raymond Andersen

  • Research Location

    Canada

  • Lead Research Institution

    University of British Columbia

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

In the search for drugs effective against SARS-CoV-2 infection, there are speed and safety advantages to repurposing existing drugs. This project will test thousands of FDA-approved drugs and other clinical-stage compounds alone and in combination with each other to see how effective they are in combating SARS-CoV-2 infections. The most promising potential therapies will be evaluated on a state-of-the-art human airway cell platform developed with collaborator and local biotech leader STEMCELL Technologies, and tested for their ability to inhibit all stages of the virus lifecycle. This project could catalyze the discovery of desperately needed candidate therapeutics for COVID-19. It also leverages the virology, drug discovery, and protein analysis expertise of an interdisciplinary, international team to create a consortium well-positioned to rapidly identify lead therapeutic candidates for emerging pathogens.